Puma Biotechnology (PBYI) Asset Writedowns and Impairment (2021 - 2025)
Puma Biotechnology (PBYI) reported Asset Writedowns and Impairment of -$100000.0 for Q3 2025, little changed on a YoY basis from -$100000.0 in Q3 2024, and up 66.67% quarter-over-quarter from -$300000.0 in Q2 2025.
Puma Biotechnology (PBYI) Asset Writedowns and Impairment (2021 - 2025) Analysis & Trends
Puma Biotechnology has reported Asset Writedowns and Impairment for 4 years, with the latest figure at -$100000.0 in Q3 2025.
- For the quarter ending Q3 2025, Asset Writedowns and Impairment changed 0.0% year-over-year to -$100000.0; the trailing twelve-month figure through Mar 2026 stood at -$400000.0 (down 2004.76% YoY), and the FY2025 full-year result was -$400000.0, changed N/A from the prior year.
- Asset Writedowns and Impairment for Q3 2025 stood at -$100000.0, up from -$300000.0 in the prior quarter.
- The five-year high for Asset Writedowns and Impairment was $1.0 million in Q4 2021, with the low at -$300000.0 in Q2 2025.
- Historically, Asset Writedowns and Impairment has averaged $134600.0 across 4 years, with a median of $105500.0 in 2023.
- Annual changes were most pronounced in 2024 — Asset Writedowns and Impairment sank 138.91% — and 2025, when it surged 100.0%.
- Puma Biotechnology's Asset Writedowns and Impairment stood at $1.0 million in 2021, then plunged by 88.9% to $111000.0 in 2023, then rose by 9.01% to $121000.0 in 2024, then slumped by 182.64% to -$100000.0 in 2025.
- The last three Asset Writedowns and Impairment figures came in at -$100000.0 (Q3 2025), -$300000.0 (Q2 2025), and $200000.0 (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Puma Biotechnology | 384.39 Mn | 282.84 Mn | 34.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -100,000.00 |
| Sep 30, 2025 | -100,000.00 |
| Jun 30, 2025 | -300,000.00 |
| Jun 30, 2025 | -300,000.00 |
| Mar 31, 2025 | 200,000.00 |
| Mar 31, 2025 | 200,000.00 |
| Dec 31, 2024 | 121,000.00 |
| Dec 31, 2024 | 121,000.00 |
| Sep 30, 2024 | -100,000.00 |
| Sep 30, 2024 | -100,000.00 |
| Jun 30, 2024 | -200,000.00 |
| Jun 30, 2024 | -200,000.00 |
| Mar 31, 2024 | 100,000.00 |
| Mar 31, 2024 | 100,000.00 |
| Dec 31, 2023 | 111,000.00 |
| Dec 31, 2023 | 111,000.00 |
| Jun 30, 2023 | 514,000.00 |
| Jun 30, 2023 | 514,000.00 |
| Dec 31, 2021 | 1.00 Mn |
| Dec 31, 2021 | 1.00 Mn |